åæ¥æ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Y-mAbs Therapeutics, Inc. ã¯ãç±³åœã§çæ²»ççšã®æ°ããæäœããŒã¹ã®æ²»ç補åã®éçºãšåæ¥åã«æ³šåããŠããŸããå瀟ã¯ãåçºãŸãã¯é£æ²»æ§ã®é«ãªã¹ã¯ç¥çµèœè
«ã®å°å
æ£è
ã®æ²»ççšã«ãé¡ç²çãã¯ããã¡ãŒãžã³ãããŒåºæ¿å åãšçµã¿åãããã¢ãã¯ããŒãã«æäœ DANYELZA ãæäŸããŠããŸããå瀟ã¯ãŸãã第äžéžæç¥çµèœè
«ã第äžéžæç¥çµèœè
«ãããã³åçºæ§éªšèè
«ã®æ£è
ã®æ²»çãç®çãšãã第 II çžèšåºè©Šéšäžã® DANYELZAãã¹ããŒãž 4 ã®é«ãªã¹ã¯ç¥çµèœè
«ã®æ²»çãç®çãšãã第 II çžèšåºè©Šéšäžã® GD2-GD3 ã¯ã¯ãã³ãéçºããŠããŸãããŸããç¥çµèœè
«ãç·ç¶åœ¢ææ§å°å圢现èè
«çãã³ãŸãæ§å
åšæ§æ©ç¥çµè è
«ããã®ä»ã®B7-H3éœæ§è
«çããã®äžæ¢ç¥çµç³»/è»èè»¢ç§»ã®æ²»çè¬ãšããŠèšåºè©Šéšäžã®ããŠã¹ã¢ãã¯ããŒãã«æäœãªã ãã«ã¿ãããéçºäžã§ãããããã«ãå°çްèèºããã®æ²»çè¬ãšããŠããããã¿ãããéçºäžã§ããã飿²»æ§ã®GD2éœæ§æäººããã³å°å
åºåœ¢è
«çã®æ²»çè¬ãšããŠç¬¬I/IIçžè©Šéšäžã§ãããããã«ãé«èœè
«ããã³åºåœ¢è
«çããã®B7-H3éœæ§è»èè»¢ç§»ã®æ²»çè¬ãšããŠç¬¬Içžèšåºéçºäžã®Lu-ãªã³ãã«ã¿ãã-DTPAãéçºäžã§ãããå瀟ã¯ãã¡ã¢ãªã¢ã«ã»ã¹ããŒã³ã»ã±ã¿ãªã³ã°ããã»ã³ã¿ãŒããã³ããµãã¥ãŒã»ããå·¥ç§å€§åŠãšã©ã€ã»ã³ã¹è£œåã®éçºããã³åååã«é¢ããã©ã€ã»ã³ã¹å¥çŽãçµãã§ãããY-mAbs Therapeutics, Inc.ã¯2015幎ã«èšç«ããããã¥ãŒãšãŒã¯å·ãã¥ãŒãšãŒã¯åžã«æ¬ç€Ÿã眮ããŠããã